knowledge -WSS

knowledge

author：hotspot 2025-10-01 23:57:18 - browse：41388

Illustration of a red human heart with an EKG line in the middle. -- health coverage from STAT — Adobe

Just weeks after Novo Nordisk announced that its obesity drug Wegovy cut the risk of heart complications in a major trial, the company now has results from a different study showing the treatment can also benefit people with a common type of heart failure.

The results, published Friday in the New England Journal of Medicine, found that among people with obesity and heart failure with preserved ejection fraction, or HFpEF, those taking Wegovy experienced greater improvements in symptoms and physical function compared with those on placebo. The improvements were greater than what’s been seen in trials of some other HFpEF treatments.

Novo previously shared topline results in investor calls, but the new study contains the full findings, which are also being presented at the European Society of Cardiology conference this week.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： Female surgeons have lower rates of long

knowledge

explore

WSS

Better Therapeutics data on benefit with GLP

Cancer cells are shown to suck energy source from immune cells

Retired US general questions alleged Putin, Prigozhin meeting

Living with Fabry disease, a condition that causes chronic pain

Peter Marks talks Operation Warp Speed for Rare Diseases

Leqembi, other new Alzheimer’s drugs require better biomarkers

Wikipedia

knowledge

explore

Dobbs anniversary: the lost opportunity of abortion as health care

Bulgari apologizes to China for listing Taiwan as a country after online backlash

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

What to know about OceanGate, the company behind the missing Titanic submersible

State Dept. review finds Biden bears some blame for Afghanistan failures

Medicare to cover more brain scans related to Alzheimer’s drugs

Virginia high school admissions case could be legal follow

STAT Readout Newsletter: Today in biotech, life science news

Duchenne breakthrough therapy leaves behind pioneering families

Lecanemab for Alzheimer's is coming. Is the health system ready?

leisure time

A new study sees potential in DNA sequencing of infants

Massive project maps cells in human brain in unprecedented detail

Why ADHD is under

Nick Jonas talks about managing diabetes along with his career

Female surgeons have lower rates of long

Nick Jonas talks about managing diabetes along with his career

knowledge

explore

hotspot

knowledge